What is Northland Securities’ Estimate for TLSI Q1 Earnings?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Stock analysts at Northland Securities issued their Q1 2026 earnings estimates for TriSalus Life Sciences in a research note issued on Friday, March 6th. Northland Securities analyst C. Byrnes forecasts that the company will earn ($0.12) per share for the quarter. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share. Northland Securities also issued estimates for TriSalus Life Sciences’ FY2027 earnings at ($0.20) EPS.

A number of other research firms have also commented on TLSI. Canaccord Genuity Group lowered their price objective on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday. Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $7.00.

TriSalus Life Sciences Trading Up 3.1%

NASDAQ TLSI opened at $4.61 on Monday. The company has a market cap of $230.78 million, a price-to-earnings ratio of -2.52 and a beta of 0.42. The company has a 50 day moving average of $5.32 and a 200-day moving average of $5.36. TriSalus Life Sciences has a 1-year low of $3.42 and a 1-year high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. The business had revenue of $13.21 million during the quarter, compared to analyst estimates of $13.20 million.

Institutional Trading of TriSalus Life Sciences

Several large investors have recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey bought a new position in shares of TriSalus Life Sciences in the second quarter worth about $29,000. JPMorgan Chase & Co. grew its holdings in shares of TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $47,000. Invesco Ltd. bought a new stake in shares of TriSalus Life Sciences in the fourth quarter worth $72,000. Finally, Abel Hall LLC acquired a new stake in TriSalus Life Sciences in the fourth quarter valued at $73,000. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.